Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Identification of predictive markers of the therapeutic effect of eribulin chemotherapy for locally advanced or metastatic breast cancer

Fig. 3

Progression-free survival of patients with MBC based on TLE3 expression. Kaplan-Meier curves of progression free survival of all patients a, of patients with TNBC lesions b and of patients with non-TNBC lesions c according to TLE3 expression. Patients with TNBC lesions that had TLE3-negative tumors experienced significantly poorer prognosis in terms of progression-free survival than those with TLE3-positive tumors (p = 0.011) b. In contrast, no significant differences were found in the progression free survival of TLE3-positive/−negative groups within all patients (p = 0.433) a or within patients with non-TNBC lesions (p = 0.659) c

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us